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Topics
• Scientific overview
• Stool collection process
•Reimbursement and billing
Colorectal cancer statistics
• Colorectal cancer (CRC) is the 3rd most common type of 
cancer and 2nd cause of cancer-related death in the US
• In 2019, estimated new CRC 145,000, ~51,000 deaths
• Estimated that more than half of all cases can be prevented 
by regular colonoscopy screening
• Lifetime risk 1 in 22
• CRC screening improved recently. 40%62% 2015. Goal 
80%
American Cancer Society (2019)
https://cancerstatisticscenter.cancer.org
Cologuard
• FDA approved in 2014
• Stool based test which detects DNA mutations
• Non-invasive screening option done at home, available by 
prescription only
• Detected 92% cancers, 69% HGD, 42% advanced adenomas
• FIT test: 74% cancers, 46% HGD, 24% advanced adenomas
• Medicare approved every 3 years, age 50-75, who are 
asymptomatic, average risk (no hx prior polyps, ca, FH of ca 
etc)
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Cologuard’s patient compliance rate is derived from the number of completed tests reported divided by 
the number of collection kits shipped to patients during the 12-month period ending 60 days prior to 
December 31, 2016.
*
Conducted by Exact Sciences Staff
>92% of all Cologuard patients have no out of pocket cost for screening
Conclusion
• Screening tests offer the best way to prevent CRC or find 
polyps early. Early detection allows for better chance for 
successful treatment
• Early CRC usually has no symptoms. Do not wait for 
symptoms to occur
• Treatment is most effective when CRC is found early
• Get appropriate screening for colorectal cancer!!!
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